Alvaro Menendez Rivera, MD
NPI 1730520776 · Northeast · Owned by Dr. Priya Anand
Deepen discussion of tx selection patterns between T-DXd + P and existing regimens for 1L HER2+ a/mBC
Driving dimension: Tx selection patterns between T-DXd + P and existing regimens for 1L HER2+ a/mBC
Impact context
An active HCP with a developing professional network. Focus on establishing a productive scientific relationship and identifying topics of clinical interest.
Knowledge context
Limited evidence exposure in this area. Lead with core clinical data and foundational context, keeping it clear and grounded in patient relevance. Let their questions set the pace for going deeper.
Suggested materials
- DESTINY-Breast09 (D967UC00001) Fam-Trastuzumab Deruxtecan-nxki (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-Positive First Line Metastatic Breast Cancer (Reactive Slide Deck; MED-US-TRAS-00436): Slides 16–37
- DESTINY-Breast09 Medical Q&A (FAQ Document; MED-US-TRAS-00437): All questions from DESTINY-Breast09 Efficacy Results, DESTINY-Breast09 Key Subgroup Analysis Results
- Discussion Guide: T-DXd+ P in 1L HER2-Positive mBC (Reactive Slide Deck; MED-US-TRAS-00412): Slides 9–14, 26–36, 42–47
Feedback timeline
Rebalance perspective on patient segmentation
Driving dimension: Patient segmentation
Impact context
An active HCP with a developing professional network. Focus on establishing a productive scientific relationship and identifying topics of clinical interest.
Knowledge context
Limited evidence exposure in this area. Lead with core clinical data and foundational context, keeping it clear and grounded in patient relevance. Let their questions set the pace for going deeper.
Suggested materials
- DESTINY-Breast09 (D967UC00001) Fam-Trastuzumab Deruxtecan-nxki (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-Positive First Line Metastatic Breast Cancer (Reactive Slide Deck; MED-US-TRAS-00436): Slides 8, 16–37
- DESTINY-Breast09 Medical Q&A (FAQ Document; MED-US-TRAS-00437): All questions from DESTINY-Breast09 Efficacy Results, DESTINY-Breast09 Safety Results, and DESTINY-Breast09 Key Subgroup Analysis Results
- Discussion Guide: T-DXd+ P in 1L HER2-Positive mBC (Reactive Slide Deck; MED-US-TRAS-00412): Slides 10–12
Feedback timeline
Discover current approach to QoL vs other regimens
Driving dimension: QoL vs other regimens
Impact context
An active HCP with a developing professional network. Focus on establishing a productive scientific relationship and identifying topics of clinical interest.
Knowledge context
Limited evidence exposure in this area. Lead with core clinical data and foundational context, keeping it clear and grounded in patient relevance. Let their questions set the pace for going deeper.